Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian M Thompson

Showing results (141-150 of 484) with videos related to

Pageof 49
Sort By:
Current Urology Reports|April 25, 2006
Prostate cancer detection strategiesTimothy C Brand, Javier Hernandez, Edith D Canby-Hagino, et al.
The American Journal of Medicine|August 9, 2005
Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancerSteven B Zeliadt, Ruth D Etzioni, David F Penson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2005
Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisitedEric A Klein, Catherine M Tangen, Phyllis J Goodman, et al.
Urology|May 6, 2008
Does the level of prostate cancer risk affect cancer prevention with finasteride?Ian M Thompson, Catherine M Tangen, Howard L Parnes, et al.
Controlled Clinical Trials|December 31, 2002
Biomarker-based methods for determining noncompliance in a prevention trialDonna K Pauler, Kathryn B Gower, Phyllis J Goodman, et al.
BMC Urology|October 3, 2015
A case control study of sarcosine as an early prostate cancer detection biomarkerDonna P Ankerst, Michael Liss, David Zapata, et al.
Urologic Oncology|May 4, 2012
The risk of biopsy-detectable prostate cancer using the prostate cancer prevention Trial Risk Calculator in a community settingYuanyuan Liang, Donna P Ankerst, Ziding Feng, et al.
The Journal of Urology|February 18, 2015
Intermediate-Term Risk of Prostate Cancer is Directly Related to Baseline Prostate Specific Antigen: Implications for Reducing the Burden of Prostate Specific Antigen ScreeningJonathan Gelfond, Kara Choate, Donna P Ankerst, et al.
Journal of the National Cancer Institute. Monographs|December 29, 2012
Temporal changes in the clinical approach to diagnosing prostate cancerWilliam M Hilton, Susan S Padalecki, Donna P Ankerst, et al.
Cancer|December 13, 2005
Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increaseAlan R Kristal, Chen Chi, Catherine M Tangen, et al.
Pageof 49

Showing results (141-150 of 484) with videos related to

Sort By:
Pageof 49
Current Urology Reports|April 25, 2006
Prostate cancer detection strategiesTimothy C Brand, Javier Hernandez, Edith D Canby-Hagino, et al.
The American Journal of Medicine|August 9, 2005
Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancerSteven B Zeliadt, Ruth D Etzioni, David F Penson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2005
Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisitedEric A Klein, Catherine M Tangen, Phyllis J Goodman, et al.
Urology|May 6, 2008
Does the level of prostate cancer risk affect cancer prevention with finasteride?Ian M Thompson, Catherine M Tangen, Howard L Parnes, et al.
Controlled Clinical Trials|December 31, 2002
Biomarker-based methods for determining noncompliance in a prevention trialDonna K Pauler, Kathryn B Gower, Phyllis J Goodman, et al.
BMC Urology|October 3, 2015
A case control study of sarcosine as an early prostate cancer detection biomarkerDonna P Ankerst, Michael Liss, David Zapata, et al.
Urologic Oncology|May 4, 2012
The risk of biopsy-detectable prostate cancer using the prostate cancer prevention Trial Risk Calculator in a community settingYuanyuan Liang, Donna P Ankerst, Ziding Feng, et al.
The Journal of Urology|February 18, 2015
Intermediate-Term Risk of Prostate Cancer is Directly Related to Baseline Prostate Specific Antigen: Implications for Reducing the Burden of Prostate Specific Antigen ScreeningJonathan Gelfond, Kara Choate, Donna P Ankerst, et al.
Journal of the National Cancer Institute. Monographs|December 29, 2012
Temporal changes in the clinical approach to diagnosing prostate cancerWilliam M Hilton, Susan S Padalecki, Donna P Ankerst, et al.
Cancer|December 13, 2005
Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increaseAlan R Kristal, Chen Chi, Catherine M Tangen, et al.
Pageof 49